Mid-stage CNS biotech Al­to Neu­ro­science files for NYSE list­ing

Cal­i­for­nia biotech Al­to Neu­ro­science has filed to go pub­lic as it runs two Phase IIb tri­als for its two lead ma­jor de­pres­sive dis­or­der drug can­di­dates.

Al­to’s Fri­day night fil­ing comes as in­vestors and start­up ex­ec­u­tives ap­pear more up­beat than last year about the pub­lic mar­kets, with in­ter­est rate cuts po­ten­tial­ly on the hori­zon and a steady drum­beat of M&A ac­tiv­i­ty in re­cent months.

The com­pa­ny plans to list on the New York Stock Ex­change as “AN­RO.” The Eli Lil­ly-backed start­up last dis­closed a $45 mil­lion Se­ries C in No­vem­ber 2023. The biotech had $51 mil­lion in cash and equiv­a­lents as of Sept. 30, per its S-1 fil­ing, and had spent $20.6 mil­lion on R&D in the first nine months of 2023, about $3 mil­lion more than the same pe­ri­od of 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER